Sign in / Join Now
ETFs & Funds
following our pipelines research completion are to build notable LONG with $
. Keep $
ADXS did reverese split...stay away
thanks! financially they're worst of all but we just follow our med.team advise sees potential in their technology (success chance over 50%)
Add a reply...
Latest StockTalks »
people get ACHN breaking news and analysis by email alert.
Get email alerts on ACHN »
Achillion Pharmaceuticals, Inc.
Get latest price
From other sites
Achillion Announces Clinical Milestone For The Advancement Of JNJ-4178 In Phase 2B Development For Chronic HCV
at TheStreet (Dec 28, 2016)
Data Presented At American Society Of Hematology Meeting Demonstrate Potential Advantages Of Factor D Inhibition For The Treatment Of Complement Alternative Pathway-Mediated Diseases
at TheStreet (Dec 5, 2016)
Achillion Announces Initiation Of Patient Dosing By Janssen In A Global, Short Treatment-Duration Phase 2b Study Of JNJ-4178 In Chronic HCV
at TheStreet (Nov 30, 2016)
Achillion Pharmaceuticals (ACHN) is Oversold: Can It Recover?
at Zacks.com (Nov 21, 2016)
Achillion Announces Upcoming Presentations Of Novel Research Into Complement Biology At The 58th Annual Meeting Of The American Society Of Hematology
at TheStreet (Nov 3, 2016)